CytomX Therapeutics, Inc. (CTMX) Stock Competitors & Peer Comparison
See (CTMX) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CTMX | $2.94 | -2.00% | 472.8M | -5.65 | -$0.52 | N/A |
| NVO | $41.02 | -4.50% | 182.2B | 9.63 | $4.26 | +4.37% |
| VRTX | $442.96 | -0.87% | 112.4B | 26.29 | $16.85 | N/A |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| REGN | $611.34 | -3.79% | 63B | 14.91 | $40.99 | +0.59% |
| ARGX | $882.41 | -1.00% | 54.6B | 39.13 | $22.55 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $292.16 | -3.59% | 39B | 73.59 | $3.97 | N/A |
| RVMD | $148.49 | -0.50% | 31.6B | -20.86 | -$7.12 | N/A |
| RPRX | $54.86 | -1.81% | 23.6B | 28.87 | $1.90 | +1.66% |
Stock Comparison
CTMX vs NVO Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, NVO has a market cap of 182.2B. Regarding current trading prices, CTMX is priced at $2.94, while NVO trades at $41.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas NVO's P/E ratio is 9.63. In terms of profitability, CTMX's ROE is -0.37%, compared to NVO's ROE of +0.66%. Regarding short-term risk, CTMX is more volatile compared to NVO. This indicates potentially higher risk in terms of short-term price fluctuations for CTMX.Check NVO's competition here
CTMX vs VRTX Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, VRTX has a market cap of 112.4B. Regarding current trading prices, CTMX is priced at $2.94, while VRTX trades at $442.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas VRTX's P/E ratio is 26.29. In terms of profitability, CTMX's ROE is -0.37%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, CTMX is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for CTMX.Check VRTX's competition here
CTMX vs VRNA Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, CTMX is priced at $2.94, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas VRNA's P/E ratio is -102.80. In terms of profitability, CTMX's ROE is -0.37%, compared to VRNA's ROE of -0.13%. Regarding short-term risk, CTMX is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for CTMX.Check VRNA's competition here
CTMX vs REGN Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, REGN has a market cap of 63B. Regarding current trading prices, CTMX is priced at $2.94, while REGN trades at $611.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas REGN's P/E ratio is 14.91. In terms of profitability, CTMX's ROE is -0.37%, compared to REGN's ROE of +0.14%. Regarding short-term risk, CTMX is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for CTMX.Check REGN's competition here
CTMX vs ARGX Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, ARGX has a market cap of 54.6B. Regarding current trading prices, CTMX is priced at $2.94, while ARGX trades at $882.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas ARGX's P/E ratio is 39.13. In terms of profitability, CTMX's ROE is -0.37%, compared to ARGX's ROE of +0.37%. Regarding short-term risk, CTMX is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for CTMX.Check ARGX's competition here
CTMX vs SGEN Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, CTMX is priced at $2.94, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas SGEN's P/E ratio is -57.19. In terms of profitability, CTMX's ROE is -0.37%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, CTMX is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for CTMX.Check SGEN's competition here
CTMX vs ALNY Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, ALNY has a market cap of 39B. Regarding current trading prices, CTMX is priced at $2.94, while ALNY trades at $292.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas ALNY's P/E ratio is 73.59. In terms of profitability, CTMX's ROE is -0.37%, compared to ALNY's ROE of +0.98%. Regarding short-term risk, CTMX is less volatile compared to ALNY. This indicates potentially lower risk in terms of short-term price fluctuations for CTMX.Check ALNY's competition here
CTMX vs RVMD Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, RVMD has a market cap of 31.6B. Regarding current trading prices, CTMX is priced at $2.94, while RVMD trades at $148.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas RVMD's P/E ratio is -20.86. In terms of profitability, CTMX's ROE is -0.37%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, CTMX is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for CTMX.Check RVMD's competition here
CTMX vs RPRX Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, RPRX has a market cap of 23.6B. Regarding current trading prices, CTMX is priced at $2.94, while RPRX trades at $54.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas RPRX's P/E ratio is 28.87. In terms of profitability, CTMX's ROE is -0.37%, compared to RPRX's ROE of +0.13%. Regarding short-term risk, CTMX is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for CTMX.Check RPRX's competition here
CTMX vs UTHR Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, UTHR has a market cap of 23.1B. Regarding current trading prices, CTMX is priced at $2.94, while UTHR trades at $544.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas UTHR's P/E ratio is 20.14. In terms of profitability, CTMX's ROE is -0.37%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, CTMX is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for CTMX.Check UTHR's competition here
CTMX vs BNTX Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, BNTX has a market cap of 21.6B. Regarding current trading prices, CTMX is priced at $2.94, while BNTX trades at $85.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas BNTX's P/E ratio is -14.54. In terms of profitability, CTMX's ROE is -0.37%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, CTMX is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for CTMX.Check BNTX's competition here
CTMX vs ROIV Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, ROIV has a market cap of 20.5B. Regarding current trading prices, CTMX is priced at $2.94, while ROIV trades at $28.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas ROIV's P/E ratio is -52.76. In terms of profitability, CTMX's ROE is -0.37%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, CTMX is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for CTMX.Check ROIV's competition here
CTMX vs INSM Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, INSM has a market cap of 20.4B. Regarding current trading prices, CTMX is priced at $2.94, while INSM trades at $94.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas INSM's P/E ratio is -16.35. In terms of profitability, CTMX's ROE is -0.37%, compared to INSM's ROE of -1.30%. Regarding short-term risk, CTMX is more volatile compared to INSM. This indicates potentially higher risk in terms of short-term price fluctuations for CTMX.Check INSM's competition here
CTMX vs BGNE Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, CTMX is priced at $2.94, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas BGNE's P/E ratio is -22.55. In terms of profitability, CTMX's ROE is -0.37%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, CTMX is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for CTMX.Check BGNE's competition here
CTMX vs INCY Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, INCY has a market cap of 20.1B. Regarding current trading prices, CTMX is priced at $2.94, while INCY trades at $100.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas INCY's P/E ratio is 14.21. In terms of profitability, CTMX's ROE is -0.37%, compared to INCY's ROE of +0.29%. Regarding short-term risk, CTMX is less volatile compared to INCY. This indicates potentially lower risk in terms of short-term price fluctuations for CTMX.Check INCY's competition here
CTMX vs MRNA Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, MRNA has a market cap of 18.9B. Regarding current trading prices, CTMX is priced at $2.94, while MRNA trades at $47.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas MRNA's P/E ratio is -5.85. In terms of profitability, CTMX's ROE is -0.37%, compared to MRNA's ROE of -0.37%. Regarding short-term risk, CTMX is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for CTMX.Check MRNA's competition here
CTMX vs DNA-WT Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, CTMX is priced at $2.94, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, CTMX's ROE is -0.37%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, CTMX is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for CTMX.Check DNA-WT's competition here
CTMX vs NBIX Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, NBIX has a market cap of 16.4B. Regarding current trading prices, CTMX is priced at $2.94, while NBIX trades at $163.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas NBIX's P/E ratio is 25.06. In terms of profitability, CTMX's ROE is -0.37%, compared to NBIX's ROE of +0.22%. Regarding short-term risk, CTMX is more volatile compared to NBIX. This indicates potentially higher risk in terms of short-term price fluctuations for CTMX.Check NBIX's competition here
CTMX vs GMAB Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, GMAB has a market cap of 15.2B. Regarding current trading prices, CTMX is priced at $2.94, while GMAB trades at $24.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas GMAB's P/E ratio is 18.79. In terms of profitability, CTMX's ROE is -0.37%, compared to GMAB's ROE of +0.15%. Regarding short-term risk, CTMX is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for CTMX.Check GMAB's competition here
CTMX vs JAZZ Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, JAZZ has a market cap of 14.6B. Regarding current trading prices, CTMX is priced at $2.94, while JAZZ trades at $232.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas JAZZ's P/E ratio is 1933.67. In terms of profitability, CTMX's ROE is -0.37%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, CTMX is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for CTMX.Check JAZZ's competition here
CTMX vs BBIO Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, BBIO has a market cap of 13.2B. Regarding current trading prices, CTMX is priced at $2.94, while BBIO trades at $67.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas BBIO's P/E ratio is -18.01. In terms of profitability, CTMX's ROE is -0.37%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, CTMX is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for CTMX.Check BBIO's competition here
CTMX vs EXEL Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, EXEL has a market cap of 13B. Regarding current trading prices, CTMX is priced at $2.94, while EXEL trades at $51.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas EXEL's P/E ratio is 17.13. In terms of profitability, CTMX's ROE is -0.37%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, CTMX is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for CTMX.Check EXEL's competition here
CTMX vs ASND Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, ASND has a market cap of 12.7B. Regarding current trading prices, CTMX is priced at $2.94, while ASND trades at $205.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas ASND's P/E ratio is 23.39. In terms of profitability, CTMX's ROE is -0.37%, compared to ASND's ROE of -56.42%. Regarding short-term risk, CTMX is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for CTMX.Check ASND's competition here
CTMX vs KRTX Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, CTMX is priced at $2.94, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas KRTX's P/E ratio is -28.09. In terms of profitability, CTMX's ROE is -0.37%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, CTMX is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for CTMX.Check KRTX's competition here
CTMX vs IONS Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, IONS has a market cap of 12.2B. Regarding current trading prices, CTMX is priced at $2.94, while IONS trades at $73.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas IONS's P/E ratio is -36.59. In terms of profitability, CTMX's ROE is -0.37%, compared to IONS's ROE of -0.59%. Regarding short-term risk, CTMX is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for CTMX.Check IONS's competition here
CTMX vs AXSM Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, AXSM has a market cap of 12.1B. Regarding current trading prices, CTMX is priced at $2.94, while AXSM trades at $235.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas AXSM's P/E ratio is -63.21. In terms of profitability, CTMX's ROE is -0.37%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, CTMX is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for CTMX.Check AXSM's competition here
CTMX vs RNAM Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, CTMX is priced at $2.94, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas RNAM's P/E ratio is -17.39. In terms of profitability, CTMX's ROE is -0.37%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, CTMX is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for CTMX.Check RNAM's competition here
CTMX vs SMMT Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, SMMT has a market cap of 10.9B. Regarding current trading prices, CTMX is priced at $2.94, while SMMT trades at $14.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas SMMT's P/E ratio is -8.87. In terms of profitability, CTMX's ROE is -0.37%, compared to SMMT's ROE of -3.41%. Regarding short-term risk, CTMX is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for CTMX.Check SMMT's competition here
CTMX vs BMRN Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, BMRN has a market cap of 10.9B. Regarding current trading prices, CTMX is priced at $2.94, while BMRN trades at $56.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas BMRN's P/E ratio is 40.68. In terms of profitability, CTMX's ROE is -0.37%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, CTMX is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for CTMX.Check BMRN's competition here
CTMX vs MDGL Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, MDGL has a market cap of 10.8B. Regarding current trading prices, CTMX is priced at $2.94, while MDGL trades at $467.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas MDGL's P/E ratio is -34.61. In terms of profitability, CTMX's ROE is -0.37%, compared to MDGL's ROE of -0.50%. Regarding short-term risk, CTMX is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for CTMX.Check MDGL's competition here
CTMX vs ARWR Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, ARWR has a market cap of 10.4B. Regarding current trading prices, CTMX is priced at $2.94, while ARWR trades at $73.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas ARWR's P/E ratio is -32.54. In terms of profitability, CTMX's ROE is -0.37%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, CTMX is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for CTMX.Check ARWR's competition here
CTMX vs RXDX Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, CTMX is priced at $2.94, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas RXDX's P/E ratio is -56.47. In terms of profitability, CTMX's ROE is -0.37%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, CTMX is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for CTMX.Check RXDX's competition here
CTMX vs KRYS Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, KRYS has a market cap of 8.9B. Regarding current trading prices, CTMX is priced at $2.94, while KRYS trades at $301.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas KRYS's P/E ratio is 40.45. In terms of profitability, CTMX's ROE is -0.37%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, CTMX is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for CTMX.Check KRYS's competition here
CTMX vs IMGN Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, CTMX is priced at $2.94, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas IMGN's P/E ratio is -111.55. In terms of profitability, CTMX's ROE is -0.37%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, CTMX is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for CTMX.Check IMGN's competition here
CTMX vs CYTK Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, CYTK has a market cap of 8.4B. Regarding current trading prices, CTMX is priced at $2.94, while CYTK trades at $67.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas CYTK's P/E ratio is -9.91. In terms of profitability, CTMX's ROE is -0.37%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, CTMX is less volatile compared to CYTK. This indicates potentially lower risk in terms of short-term price fluctuations for CTMX.Check CYTK's competition here
CTMX vs HALO Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, HALO has a market cap of 8.4B. Regarding current trading prices, CTMX is priced at $2.94, while HALO trades at $70.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas HALO's P/E ratio is 24.82. In terms of profitability, CTMX's ROE is -0.37%, compared to HALO's ROE of +1.26%. Regarding short-term risk, CTMX is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for CTMX.Check HALO's competition here
CTMX vs BPMC Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, CTMX is priced at $2.94, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas BPMC's P/E ratio is -51.58. In terms of profitability, CTMX's ROE is -0.37%, compared to BPMC's ROE of -0.15%. Regarding short-term risk, CTMX is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for CTMX.Check BPMC's competition here
CTMX vs TECH Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, TECH has a market cap of 8.2B. Regarding current trading prices, CTMX is priced at $2.94, while TECH trades at $52.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas TECH's P/E ratio is 75.21. In terms of profitability, CTMX's ROE is -0.37%, compared to TECH's ROE of +0.05%. Regarding short-term risk, CTMX is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for CTMX.Check TECH's competition here
CTMX vs CERE Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, CTMX is priced at $2.94, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas CERE's P/E ratio is -16.47. In terms of profitability, CTMX's ROE is -0.37%, compared to CERE's ROE of -0.72%. Regarding short-term risk, CTMX is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for CTMX.Check CERE's competition here
CTMX vs CORT Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, CORT has a market cap of 7.9B. Regarding current trading prices, CTMX is priced at $2.94, while CORT trades at $73.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas CORT's P/E ratio is 209.51. In terms of profitability, CTMX's ROE is -0.37%, compared to CORT's ROE of +0.08%. Regarding short-term risk, CTMX is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for CTMX.Check CORT's competition here
CTMX vs IBRX Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, IBRX has a market cap of 7.5B. Regarding current trading prices, CTMX is priced at $2.94, while IBRX trades at $7.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas IBRX's P/E ratio is -8.44. In terms of profitability, CTMX's ROE is -0.37%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, CTMX is more volatile compared to IBRX. This indicates potentially higher risk in terms of short-term price fluctuations for CTMX.Check IBRX's competition here
CTMX vs MTSR Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, CTMX is priced at $2.94, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas MTSR's P/E ratio is -23.58. In terms of profitability, CTMX's ROE is -0.37%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, CTMX is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for CTMX.Check MTSR's competition here
CTMX vs ALKS Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, ALKS has a market cap of 7.1B. Regarding current trading prices, CTMX is priced at $2.94, while ALKS trades at $42.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas ALKS's P/E ratio is 47.17. In terms of profitability, CTMX's ROE is -0.37%, compared to ALKS's ROE of +0.09%. Regarding short-term risk, CTMX is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for CTMX.Check ALKS's competition here
CTMX vs MRUS Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, CTMX is priced at $2.94, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas MRUS's P/E ratio is -17.05. In terms of profitability, CTMX's ROE is -0.37%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, CTMX is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for CTMX.Check MRUS's competition here
CTMX vs ACLX Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, CTMX is priced at $2.94, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas ACLX's P/E ratio is -28.27. In terms of profitability, CTMX's ROE is -0.37%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, CTMX is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for CTMX.Check ACLX's competition here
CTMX vs PCVX Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, PCVX has a market cap of 6.7B. Regarding current trading prices, CTMX is priced at $2.94, while PCVX trades at $46.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas PCVX's P/E ratio is -6.72. In terms of profitability, CTMX's ROE is -0.37%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, CTMX is less volatile compared to PCVX. This indicates potentially lower risk in terms of short-term price fluctuations for CTMX.Check PCVX's competition here
CTMX vs ABVX Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, ABVX has a market cap of 6.7B. Regarding current trading prices, CTMX is priced at $2.94, while ABVX trades at $101.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas ABVX's P/E ratio is -18.94. In terms of profitability, CTMX's ROE is -0.37%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, CTMX is less volatile compared to ABVX. This indicates potentially lower risk in terms of short-term price fluctuations for CTMX.Check ABVX's competition here
CTMX vs RETA Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, CTMX is priced at $2.94, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas RETA's P/E ratio is -66.29. In terms of profitability, CTMX's ROE is -0.37%, compared to RETA's ROE of +0.47%. Regarding short-term risk, CTMX is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for CTMX.Check RETA's competition here
CTMX vs NUVL Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, NUVL has a market cap of 6.5B. Regarding current trading prices, CTMX is priced at $2.94, while NUVL trades at $88.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas NUVL's P/E ratio is -14.60. In terms of profitability, CTMX's ROE is -0.37%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, CTMX is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for CTMX.Check NUVL's competition here
CTMX vs IMVT Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, IMVT has a market cap of 6.3B. Regarding current trading prices, CTMX is priced at $2.94, while IMVT trades at $30.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas IMVT's P/E ratio is -11.12. In terms of profitability, CTMX's ROE is -0.37%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, CTMX is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for CTMX.Check IMVT's competition here
CTMX vs PTGX Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, PTGX has a market cap of 6.3B. Regarding current trading prices, CTMX is priced at $2.94, while PTGX trades at $98.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas PTGX's P/E ratio is -54.16. In terms of profitability, CTMX's ROE is -0.37%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, CTMX is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for CTMX.Check PTGX's competition here
CTMX vs TGTX Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, TGTX has a market cap of 6.3B. Regarding current trading prices, CTMX is priced at $2.94, while TGTX trades at $40.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas TGTX's P/E ratio is 14.32. In terms of profitability, CTMX's ROE is -0.37%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, CTMX is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for CTMX.Check TGTX's competition here
CTMX vs CNTA Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, CNTA has a market cap of 6.1B. Regarding current trading prices, CTMX is priced at $2.94, while CNTA trades at $39.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas CNTA's P/E ratio is -22.30. In terms of profitability, CTMX's ROE is -0.37%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, CTMX is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for CTMX.Check CNTA's competition here
CTMX vs KYMR Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, KYMR has a market cap of 6.1B. Regarding current trading prices, CTMX is priced at $2.94, while KYMR trades at $73.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas KYMR's P/E ratio is -20.66. In terms of profitability, CTMX's ROE is -0.37%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, CTMX is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for CTMX.Check KYMR's competition here
CTMX vs RYTM Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, RYTM has a market cap of 5.9B. Regarding current trading prices, CTMX is priced at $2.94, while RYTM trades at $85.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas RYTM's P/E ratio is -27.45. In terms of profitability, CTMX's ROE is -0.37%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, CTMX is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for CTMX.Check RYTM's competition here
CTMX vs PTCT Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, PTCT has a market cap of 5.9B. Regarding current trading prices, CTMX is priced at $2.94, while PTCT trades at $70.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas PTCT's P/E ratio is -27.90. In terms of profitability, CTMX's ROE is -0.37%, compared to PTCT's ROE of +1.00%. Regarding short-term risk, CTMX is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for CTMX.Check PTCT's competition here
CTMX vs LEGN Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, LEGN has a market cap of 5.8B. Regarding current trading prices, CTMX is priced at $2.94, while LEGN trades at $31.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas LEGN's P/E ratio is -22.84. In terms of profitability, CTMX's ROE is -0.37%, compared to LEGN's ROE of -0.25%. Regarding short-term risk, CTMX is less volatile compared to LEGN. This indicates potentially lower risk in terms of short-term price fluctuations for CTMX.Check LEGN's competition here
CTMX vs LQDA Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, LQDA has a market cap of 5.7B. Regarding current trading prices, CTMX is priced at $2.94, while LQDA trades at $63.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas LQDA's P/E ratio is 375.88. In terms of profitability, CTMX's ROE is -0.37%, compared to LQDA's ROE of +0.47%. Regarding short-term risk, CTMX is less volatile compared to LQDA. This indicates potentially lower risk in terms of short-term price fluctuations for CTMX.Check LQDA's competition here
CTMX vs CDTX Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, CTMX is priced at $2.94, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas CDTX's P/E ratio is -19.77. In terms of profitability, CTMX's ROE is -0.37%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, CTMX is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for CTMX.Check CDTX's competition here
CTMX vs BLTE Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, BLTE has a market cap of 5.6B. Regarding current trading prices, CTMX is priced at $2.94, while BLTE trades at $139.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas BLTE's P/E ratio is -54.97. In terms of profitability, CTMX's ROE is -0.37%, compared to BLTE's ROE of -0.27%. Regarding short-term risk, CTMX is more volatile compared to BLTE. This indicates potentially higher risk in terms of short-term price fluctuations for CTMX.Check BLTE's competition here
CTMX vs ABCM Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, CTMX is priced at $2.94, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, CTMX's ROE is -0.37%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, CTMX is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for CTMX.Check ABCM's competition here
CTMX vs ISEE Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, CTMX is priced at $2.94, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas ISEE's P/E ratio is -22.44. In terms of profitability, CTMX's ROE is -0.37%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, CTMX is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for CTMX.Check ISEE's competition here
CTMX vs PRAX Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, PRAX has a market cap of 5.4B. Regarding current trading prices, CTMX is priced at $2.94, while PRAX trades at $253.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas PRAX's P/E ratio is -18.91. In terms of profitability, CTMX's ROE is -0.37%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, CTMX is less volatile compared to PRAX. This indicates potentially lower risk in terms of short-term price fluctuations for CTMX.Check PRAX's competition here
CTMX vs COGT Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, COGT has a market cap of 5.3B. Regarding current trading prices, CTMX is priced at $2.94, while COGT trades at $31.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas COGT's P/E ratio is -14.36. In terms of profitability, CTMX's ROE is -0.37%, compared to COGT's ROE of -0.83%. Regarding short-term risk, CTMX is more volatile compared to COGT. This indicates potentially higher risk in terms of short-term price fluctuations for CTMX.Check COGT's competition here
CTMX vs FBIOX Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, FBIOX has a market cap of 5.3B. Regarding current trading prices, CTMX is priced at $2.94, while FBIOX trades at $24.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas FBIOX's P/E ratio is N/A. In terms of profitability, CTMX's ROE is -0.37%, compared to FBIOX's ROE of +0.00%. Regarding short-term risk, CTMX is more volatile compared to FBIOX. This indicates potentially higher risk in terms of short-term price fluctuations for CTMX.Check FBIOX's competition here
CTMX vs APLS Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, CTMX is priced at $2.94, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas APLS's P/E ratio is 38.35. In terms of profitability, CTMX's ROE is -0.37%, compared to APLS's ROE of +0.40%. Regarding short-term risk, CTMX is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for CTMX.Check APLS's competition here
CTMX vs SRRK Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, SRRK has a market cap of 5.2B. Regarding current trading prices, CTMX is priced at $2.94, while SRRK trades at $43.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas SRRK's P/E ratio is -12.70. In terms of profitability, CTMX's ROE is -0.37%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, CTMX is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for CTMX.Check SRRK's competition here
CTMX vs APGE Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, APGE has a market cap of 5.1B. Regarding current trading prices, CTMX is priced at $2.94, while APGE trades at $83.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas APGE's P/E ratio is -19.17. In terms of profitability, CTMX's ROE is -0.37%, compared to APGE's ROE of -0.33%. Regarding short-term risk, CTMX is less volatile compared to APGE. This indicates potentially lower risk in terms of short-term price fluctuations for CTMX.Check APGE's competition here
CTMX vs CRSP Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, CRSP has a market cap of 5B. Regarding current trading prices, CTMX is priced at $2.94, while CRSP trades at $51.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas CRSP's P/E ratio is -8.36. In terms of profitability, CTMX's ROE is -0.37%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, CTMX is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for CTMX.Check CRSP's competition here
CTMX vs CGON Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, CGON has a market cap of 4.8B. Regarding current trading prices, CTMX is priced at $2.94, while CGON trades at $54.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas CGON's P/E ratio is -23.25. In terms of profitability, CTMX's ROE is -0.37%, compared to CGON's ROE of -0.23%. Regarding short-term risk, CTMX is more volatile compared to CGON. This indicates potentially higher risk in terms of short-term price fluctuations for CTMX.Check CGON's competition here
CTMX vs TERN Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, CTMX is priced at $2.94, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas TERN's P/E ratio is -51.41. In terms of profitability, CTMX's ROE is -0.37%, compared to TERN's ROE of -0.20%. Regarding short-term risk, CTMX is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for CTMX.Check TERN's competition here
CTMX vs LGND Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, LGND has a market cap of 4.8B. Regarding current trading prices, CTMX is priced at $2.94, while LGND trades at $237.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas LGND's P/E ratio is 30.96. In terms of profitability, CTMX's ROE is -0.37%, compared to LGND's ROE of +0.16%. Regarding short-term risk, CTMX is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for CTMX.Check LGND's competition here
CTMX vs MIRM Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, MIRM has a market cap of 4.7B. Regarding current trading prices, CTMX is priced at $2.94, while MIRM trades at $93.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas MIRM's P/E ratio is -6.88. In terms of profitability, CTMX's ROE is -0.37%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, CTMX is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for CTMX.Check MIRM's competition here
CTMX vs CAI Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, CAI has a market cap of 4.6B. Regarding current trading prices, CTMX is priced at $2.94, while CAI trades at $16.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas CAI's P/E ratio is -5.85. In terms of profitability, CTMX's ROE is -0.37%, compared to CAI's ROE of +0.06%. Regarding short-term risk, CTMX is less volatile compared to CAI. This indicates potentially lower risk in terms of short-term price fluctuations for CTMX.Check CAI's competition here
CTMX vs FOLD Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, CTMX is priced at $2.94, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas FOLD's P/E ratio is -161.00. In terms of profitability, CTMX's ROE is -0.37%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, CTMX is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for CTMX.Check FOLD's competition here
CTMX vs AKRO Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, CTMX is priced at $2.94, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas AKRO's P/E ratio is -14.57. In terms of profitability, CTMX's ROE is -0.37%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, CTMX is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for CTMX.Check AKRO's competition here
CTMX vs ALPN Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, CTMX is priced at $2.94, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas ALPN's P/E ratio is -101.52. In terms of profitability, CTMX's ROE is -0.37%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, CTMX is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for CTMX.Check ALPN's competition here
CTMX vs TVTX Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, TVTX has a market cap of 4.4B. Regarding current trading prices, CTMX is priced at $2.94, while TVTX trades at $47.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas TVTX's P/E ratio is -94.16. In terms of profitability, CTMX's ROE is -0.37%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, CTMX is more volatile compared to TVTX. This indicates potentially higher risk in terms of short-term price fluctuations for CTMX.Check TVTX's competition here
CTMX vs SYRE Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, SYRE has a market cap of 4.3B. Regarding current trading prices, CTMX is priced at $2.94, while SYRE trades at $72.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas SYRE's P/E ratio is -33.96. In terms of profitability, CTMX's ROE is -0.37%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, CTMX is less volatile compared to SYRE. This indicates potentially lower risk in terms of short-term price fluctuations for CTMX.Check SYRE's competition here
CTMX vs CELC Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, CELC has a market cap of 4.3B. Regarding current trading prices, CTMX is priced at $2.94, while CELC trades at $87.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas CELC's P/E ratio is -22.42. In terms of profitability, CTMX's ROE is -0.37%, compared to CELC's ROE of -2.45%. Regarding short-term risk, CTMX is less volatile compared to CELC. This indicates potentially lower risk in terms of short-term price fluctuations for CTMX.Check CELC's competition here
CTMX vs OPT Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, CTMX is priced at $2.94, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas OPT's P/E ratio is -1.52. In terms of profitability, CTMX's ROE is -0.37%, compared to OPT's ROE of +1.09%. Regarding short-term risk, CTMX is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for CTMX.Check OPT's competition here
CTMX vs MRTX Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, CTMX is priced at $2.94, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas MRTX's P/E ratio is -4.82. In terms of profitability, CTMX's ROE is -0.37%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, CTMX is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for CTMX.Check MRTX's competition here
CTMX vs XENE Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, XENE has a market cap of 4B. Regarding current trading prices, CTMX is priced at $2.94, while XENE trades at $51.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas XENE's P/E ratio is -10.90. In terms of profitability, CTMX's ROE is -0.37%, compared to XENE's ROE of -0.49%. Regarding short-term risk, CTMX is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for CTMX.Check XENE's competition here
CTMX vs ERAS Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, ERAS has a market cap of 4B. Regarding current trading prices, CTMX is priced at $2.94, while ERAS trades at $12.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas ERAS's P/E ratio is -13.84. In terms of profitability, CTMX's ROE is -0.37%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, CTMX is less volatile compared to ERAS. This indicates potentially lower risk in terms of short-term price fluctuations for CTMX.Check ERAS's competition here
CTMX vs CPRX Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, CPRX has a market cap of 3.8B. Regarding current trading prices, CTMX is priced at $2.94, while CPRX trades at $31.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas CPRX's P/E ratio is 18.08. In terms of profitability, CTMX's ROE is -0.37%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, CTMX is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for CTMX.Check CPRX's competition here
CTMX vs MANE Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, MANE has a market cap of 3.8B. Regarding current trading prices, CTMX is priced at $2.94, while MANE trades at $90.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas MANE's P/E ratio is -34.12. In terms of profitability, CTMX's ROE is -0.37%, compared to MANE's ROE of -0.95%. Regarding short-term risk, CTMX is less volatile compared to MANE. This indicates potentially lower risk in terms of short-term price fluctuations for CTMX.Check MANE's competition here
CTMX vs VCYT Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, VCYT has a market cap of 3.8B. Regarding current trading prices, CTMX is priced at $2.94, while VCYT trades at $47.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas VCYT's P/E ratio is 43.77. In terms of profitability, CTMX's ROE is -0.37%, compared to VCYT's ROE of +0.07%. Regarding short-term risk, CTMX is more volatile compared to VCYT. This indicates potentially higher risk in terms of short-term price fluctuations for CTMX.Check VCYT's competition here
CTMX vs RYZB Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, CTMX is priced at $2.94, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas RYZB's P/E ratio is -57.86. In terms of profitability, CTMX's ROE is -0.37%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, CTMX is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for CTMX.Check RYZB's competition here
CTMX vs EWTX Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, EWTX has a market cap of 3.7B. Regarding current trading prices, CTMX is priced at $2.94, while EWTX trades at $34.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas EWTX's P/E ratio is -20.99. In terms of profitability, CTMX's ROE is -0.37%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, CTMX is more volatile compared to EWTX. This indicates potentially higher risk in terms of short-term price fluctuations for CTMX.Check EWTX's competition here
CTMX vs CBAY Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, CTMX is priced at $2.94, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas CBAY's P/E ratio is -32.81. In terms of profitability, CTMX's ROE is -0.37%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, CTMX is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for CTMX.Check CBAY's competition here
CTMX vs ACAD Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, ACAD has a market cap of 3.7B. Regarding current trading prices, CTMX is priced at $2.94, while ACAD trades at $21.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas ACAD's P/E ratio is 9.82. In terms of profitability, CTMX's ROE is -0.37%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, CTMX is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for CTMX.Check ACAD's competition here
CTMX vs KNSA Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, KNSA has a market cap of 3.7B. Regarding current trading prices, CTMX is priced at $2.94, while KNSA trades at $49.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas KNSA's P/E ratio is 53.89. In terms of profitability, CTMX's ROE is -0.37%, compared to KNSA's ROE of +0.13%. Regarding short-term risk, CTMX is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for CTMX.Check KNSA's competition here
CTMX vs NAMS Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, NAMS has a market cap of 3.6B. Regarding current trading prices, CTMX is priced at $2.94, while NAMS trades at $30.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas NAMS's P/E ratio is -17.39. In terms of profitability, CTMX's ROE is -0.37%, compared to NAMS's ROE of -0.30%. Regarding short-term risk, CTMX is less volatile compared to NAMS. This indicates potentially lower risk in terms of short-term price fluctuations for CTMX.Check NAMS's competition here
CTMX vs TNGX Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, TNGX has a market cap of 3.6B. Regarding current trading prices, CTMX is priced at $2.94, while TNGX trades at $30.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas TNGX's P/E ratio is -37.27. In terms of profitability, CTMX's ROE is -0.37%, compared to TNGX's ROE of -0.42%. Regarding short-term risk, CTMX is less volatile compared to TNGX. This indicates potentially lower risk in terms of short-term price fluctuations for CTMX.Check TNGX's competition here
CTMX vs SWTX Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, CTMX is priced at $2.94, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas SWTX's P/E ratio is -13.78. In terms of profitability, CTMX's ROE is -0.37%, compared to SWTX's ROE of -0.36%. Regarding short-term risk, CTMX is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for CTMX.Check SWTX's competition here
CTMX vs CRNX Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, CRNX has a market cap of 3.5B. Regarding current trading prices, CTMX is priced at $2.94, while CRNX trades at $33.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas CRNX's P/E ratio is -6.51. In terms of profitability, CTMX's ROE is -0.37%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, CTMX is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for CTMX.Check CRNX's competition here
CTMX vs VKTX Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, VKTX has a market cap of 3.4B. Regarding current trading prices, CTMX is priced at $2.94, while VKTX trades at $29.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas VKTX's P/E ratio is -7.05. In terms of profitability, CTMX's ROE is -0.37%, compared to VKTX's ROE of -0.71%. Regarding short-term risk, CTMX is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for CTMX.Check VKTX's competition here
CTMX vs DNTH Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, DNTH has a market cap of 3.4B. Regarding current trading prices, CTMX is priced at $2.94, while DNTH trades at $81.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas DNTH's P/E ratio is -19.20. In terms of profitability, CTMX's ROE is -0.37%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, CTMX is more volatile compared to DNTH. This indicates potentially higher risk in terms of short-term price fluctuations for CTMX.Check DNTH's competition here
CTMX vs TLX Comparison June 2026
CTMX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTMX stands at 472.8M. In comparison, TLX has a market cap of 3.1B. Regarding current trading prices, CTMX is priced at $2.94, while TLX trades at $9.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTMX currently has a P/E ratio of -5.65, whereas TLX's P/E ratio is -461.00. In terms of profitability, CTMX's ROE is -0.37%, compared to TLX's ROE of -0.02%. Regarding short-term risk, CTMX is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for CTMX.Check TLX's competition here